Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson’s disease

[1]  B. Schüle,et al.  Advancing Stem Cell Models of Alpha-Synuclein Gene Regulation in Neurodegenerative Disease , 2018, Front. Neurosci..

[2]  T. E. Wilson,et al.  Fragile sites in cancer: more than meets the eye , 2017, Nature Reviews Cancer.

[3]  K. Chung,et al.  Covalent ISG15 conjugation positively regulates the ubiquitin E3 ligase activity of parkin , 2016, Open Biology.

[4]  M. Cubillos-Rojas,et al.  Functional and pathological relevance of HERC family proteins: a decade later , 2016, Cellular and Molecular Life Sciences.

[5]  T. Jovin,et al.  Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells , 2015, Cell Death and Disease.

[6]  D. Dickson,et al.  Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations. , 2013, American journal of neurodegenerative disease.

[7]  Richard L. Doty,et al.  Olfaction in Parkinson's disease and related disorders , 2012, Neurobiology of Disease.

[8]  Richard L. Doty,et al.  Olfactory dysfunction in Parkinson disease , 2012, Nature Reviews Neurology.

[9]  Deanna S. Smith,et al.  A Cdk5-Dependent Switch Regulates Lis1/Ndel1/Dynein-Driven Organelle Transport in Adult Axons , 2011, The Journal of Neuroscience.

[10]  Lief E. Fenno,et al.  SNCA Triplication Parkinson's Patient's iPSC-derived DA Neurons Accumulate α-Synuclein and Are Susceptible to Oxidative Stress , 2011, PloS one.

[11]  A. López de Munain,et al.  Olfactory deficits and cardiac 123I‐MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations , 2011, Movement disorders : official journal of the Movement Disorder Society.

[12]  M. Swartz.  A decade later. , 2011, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.

[13]  R. Lipton,et al.  Olfactory dysfunction in LRRK2 G2019S mutation carriers , 2011, Neurology.

[14]  A. Lees,et al.  Olfactory heterogeneity in LRRK2 related Parkinsonism , 2010, Movement disorders : official journal of the Movement Disorder Society.

[15]  H. Siebner,et al.  Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[16]  C. Tanner,et al.  Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[17]  C. Adler,et al.  Evaluation of α-synuclein immunohistochemical methods used by invited experts , 2008, Acta Neuropathologica.

[18]  M. Farrer,et al.  Genomic investigation of α‐synuclein multiplication and parkinsonism , 2008, Annals of neurology.

[19]  G. Izzi,et al.  A case of colloid milium in patient with β thalassaemia major , 2008, Journal of cutaneous pathology.

[20]  Isidro Ferrer,et al.  Argyrophilic grain disease. , 2008, Brain : a journal of neurology.

[21]  M. Farrer,et al.  Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication , 2007, Neurology.

[22]  A. Porta,et al.  Early Abnormalities of Vascular and Cardiac Autonomic Control in Parkinson’s Disease Without Orthostatic Hypotension , 2007, Hypertension.

[23]  A. Herskovits,et al.  The regulation of tau phosphorylation by PCTAIRE 3: Implications for the pathogenesis of Alzheimer's disease , 2006, Neurobiology of Disease.

[24]  A. Singleton,et al.  Clinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease , 2006 .

[25]  Masahito Yamada,et al.  Significance of123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: It can be a specific marker for Lewy body disease , 2004, Annals of nuclear medicine.

[26]  S. Nee.  More than meets the eye , 2004, Nature.

[27]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[28]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[29]  A Sahraie,et al.  New Farnsworth-Munsell 100 hue test norms of normal observers for each year of age 5–22 and for age decades 30–70 , 2002, The British journal of ophthalmology.

[30]  M. Farrer,et al.  Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p , 2000, Acta Neuropathologica.

[31]  K. Iwanaga,et al.  Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  H Okazaki,et al.  Hereditary form of parkinsonism—dementia , 1998, Annals of neurology.

[33]  C. Waters,et al.  Autosomal dominant Lewy body parkinsonism in a four‐generation family , 1994, Annals of neurology.

[34]  D. Innocenzi,et al.  UV‐induced colloid milium , 1993, Clinical and experimental dermatology.

[35]  I. Simson,et al.  Exogenous ochronosis and pigmented colloid milium from hydroquinone bleaching creams , 1975, The British journal of dermatology.

[36]  G. Spellman.  Report of familial cases of parkinsonism. Evidence of a dominant trait in a patient's family. , 1962, JAMA.

[37]  A. Destée,et al.  Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. , 2009, Archives of neurology.

[38]  A. Singleton,et al.  Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. , 2006, Annals of neurology.

[39]  M. Farrer,et al.  Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.

[40]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[41]  K. Nishigaki,et al.  Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.